Tempus AI
Overview
Precision medicine company combining genomic diagnostic testing with one of the largest multimodal clinical and molecular real-world datasets, licensed to life sciences companies for research and evidence generation. Its Lens platform provides AI-driven analytics over de-identified clinical, genomic, and imaging data.
Notable
IPO on Nasdaq in June 2024; data and services clients include AstraZeneca, Gilead, and Daiichi Sankyo; reports that 19 of the top 20 biopharma companies use its platform.
Key services
- multimodal clinical-genomic data licensing
- Lens data analytics platform
- evidence generation and biomarker studies
- companion diagnostics development
- clinical trial matching
Subcategories
Verified Reviews
No verified reviews yet — are you a customer of Tempus AI? Share your experience in a short, confidential interview.
Share your experience